Combination of the chemokine receptor type 2 (CCR2) antagonist DMX-200 and candesartan for COVID-19: a randomised controlled trial.

ABSTRACT:

Objective

To determine whether a chemokine receptor type 2 antagonist, DMX-200 (repagermanium), in combination with an angiotensin receptor blocker, candesartan, improves clinical outcomes in people with COVID-19.

Design

Prospective, multicentre, double-blind, placebo-controlled trial.

Setting

Ten acute care hospitals in India.

Participants

Adults <65 years old intended for hospital admission with moderate/severe COVID-19 disease (respiratory rate ≥24 breaths per minute or oxygen saturation ≤93% on room air).

Intervention

DMX-200 120 mg two times per day, or placebo, on background of titratable candesartan commencing at 4 mg two times per day, for 28 days.

Main outcome measures

The primary endpoint was COVID-19 disease severity on a modified WHO C

SUBMITTER: O'Hara DV 

PROVIDER: S-EPMC11499840 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature